Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease
Regardless of baseline CV risk, upadacitinib demonstrated comparable safety to adalimumab, except for higher rates of herpes zoster in both CV risk groups and NMSC and serious infections in the higher-risk group. Upadacitinib consistently showed better clinical and functional outcomes than adalimumab. The benefit-risk profile of upadacitinib in RA patients was favourable, independent of CV risk category, in both short and long term.
Authors
- Eduardo Mysler (ORCID: https://orcid.org/0000-0002-8993-0313)
- Tianming Gao (ORCID: https://orcid.org/0000-0003-4594-9052)
- Bettina Wick-Urban
- Stephen Hall (ORCID: https://orcid.org/0000-0002-3185-6296)
- Andrew Garrison
- Roy Fleischmann (ORCID: https://orcid.org/0000-0002-6630-1477)
- Gerd R Burmester (ORCID: https://orcid.org/0000-0001-7518-1131)
- Sander Strengholt
- Irina Fish
- Peter C. Taylor (ORCID: https://orcid.org/0000-0001-7766-6167)
Institutions
- Nuffield Orthopaedic Centre (GB)
- AbbVie (United States) (US)
- University of Oxford (GB)
- Metroplex Clinical Research Center (US)
- Southwestern Medical Center (US)
- Monash University (AU)
- Charité - Universitätsmedizin Berlin (DE)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- RMD Open
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/rmdopen-2024-005371
- Citations
- 2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- AbbVie